Roundhill Magnificent Seven ETF vs Teladoc Health Inc — how do they compare? Roundhill Magnificent Seven ETF trades at $73.73 (market cap $5.78B), while Teladoc Health Inc trades at $5.77 (market cap $1.01B). The key difference: Roundhill Magnificent Seven ETF is far larger — about 5.7× Teladoc Health Inc's market cap, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and Teladoc Health Inc for 39 Days on average.
| MAGS | TDOC | |
|---|---|---|
Market Cap | $5.78B | $1.01B |
Volume | 4,410,665 | 4,668,477 |
Sector | Sector/Thematic | Health |
52-Week High | $73.90 | $9.72 |
52-Week Low | $55.39 | $4.47 |
Typical Hold Time | 36 Days | 39 Days |
Enterprise Value | — | $1.27B |
Signals from Pluang's Aura AI — not financial advice
MAGS trades at $73.03, down 0.9% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides equal-weighted exposure to the Magnificent Seven tech stocks, though 2026 performance has been muted with a 2% year-to-date gain as the group faces increased competition and AI spending pressures. Recent news highlights both the long-term AI growth theme and near-term underperformance versus the broader market.
The outlook hinges on AI-driven earnings growth from its mega-cap holdings, but concentration risk and shifting investor sentiment pose challenges. Upside potential exists if the Magnificent Seven reassert leadership, while downside risks include prolonged sector rotation and margin compression from heavy capital expenditure.
Teladoc Health (TDOC) trades at $5.54, down 0.36% on the day, as the stock faces bearish technical momentum despite recent earnings beats. The company maintains strong revenue around $2.5B annually but continues to report net losses, with a -7.13% net income margin in 2026. Analyst sentiment is mixed with 35.7% buy ratings but a consensus price target of $8.83 suggesting 59% upside potential. Recent CFO appointment and legal officer transitions signal management changes amid ongoing operational challenges.
TDOC presents a high-risk opportunity with significant valuation discount (P/S 0.4x) but faces persistent profitability challenges. The integrated care business shows promise with improving margins, while BetterHelp weakness and negative cash flow in 2025 raise concerns. Upside depends on successful execution of turnaround strategy and achieving sustainable profitability in the competitive telehealth market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →